Inebilizumab for Treatment of IgG4-Related Disease
NEJM 392:1168-1177, Stone,J.H.,et al, 2025
Beyond Glucocorticoids for IgG4-Related Disease
NEJM 392:1232-1233, Spiera,R., 2025
Lenvatinib Therapy for Advanced Thyroid Cancer: Real-Life Data on Safety, Efficacy, and Some Rare Side Effects
JENDSO 6:1-7, Hamidi, S.,et al, 2022
Interim Results from the CATNON trial (EORTC study 260-53-22054) of treatment with Concurrent and Adjuvant Temozolomide for 1p/19q non-co-deleted anaplastic glioma: A phase 3, randomized, open-label intergroup study
Lancet 390:1645-1653, Van Den Bent, M.J.,et al, 2017
Safety and Diagnostic Value of Brain Biopsy in HIV patients: a Case Series and Meta-Analysis of 1209 Patients
JNNP 87:722-733, Lee, A.M.,et al, 2016
Randomized Phase III Study of Whole-Brain Radiotherapy for Primary CNS Lymphoma
Neurol 84:1242-1248, Korfel, A.,et al, 2015
Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis
NEJM 373:1418-1428, Kappos, L.,et al, 2015
Maintenance Therapy with Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma
JAMA 314:2535-2543,2511, Stupp, R.,et al, 2015
Mycophenolate Mofetil in Multiple Sclerosis: A Multicentre Retrospective Study on 344 Patients
JNNP 85:279-283,246, Michel, L.,et al, 2014
CT Angiography Findings in Carotid Blowout Syndrome and Its Role as a Predictor of 1-Year Survival
AJNR35:562-567, Lee, C-W.,et al, 2014
MATILDE Chemotherapy Regimen for Primary CNS Lymphoma
Neurol 82:1370-1373, Ferreri, A.J.M.,et al, 2014
Everolimus Long-Term Safety and Efficacy in Subependymal Giant Cell Astrocytoma
Neurol 80:574-580, Krueger, D.,et al, 2013
Interferon beta for Secondary Progressive Multiple Sclerosis: A Systematic Review
JNNP 84:420-426, La Mantia, L.,et al, 2013
Evidence-based Guideline Update: Steroids and Antivirals for Bell Palsy
Neurol 79:2209-2213, Gronseth, G. & Paduga, R., 2012
The use of rituximab in myasthenia gravis and Lambert--Eaton myasthenic syndrome
JNNP 82:671-673, Maddison, P.,et al, 2011
Use and monitoring of low dose rituximab in myasthenia gravis
JNNP 82:659-663, Blum, S., et al, 2011
Efficacy and Safety of Mitoxantrone in Patients with Highly Relapsing Neuromyelitis Optica
Arch Neurol 68:473-479, Kim, S.H.,et al, 2011
Reversible Cerebral Vasoconstruction Syndromes
Arch Neurol 68:1005-1012,976, Singhal, A.B.,et al, 2011
Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis
NEJM 365:1293-1303, OConnor, P.,et al, 2011
A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis
NEJM 362:416-426, 456, Giovannoni,G.,et al, 2010
Acyclovir Resistance in Herpes Simplex Encephalitis
Ann Neurol 67:830-833, Schulte,E.C., et al, 2010
Treatment of CNS Sarcoidosis with Infliximab and Mycophenolate Mofetil
Neurol 72:337-340, Morovan,M. &Segal,B.M., 2009
Antivenom for Critically Ill Children with Neurotoxicity from Scorpion Stings
NEJM 360:2090-2098, Boyer,L.V.,et al, 2009
High-Dose Cytarabine Plus High-Dose Methotrexate Versus High-Dose Methotrexate Alone in Patients with Primary CNS Lymphoma: A Randomised Phase 2 Trial
Lancet 374:1512-1520, 1477, Ferreri,A.,et al, 2009
Long-Term Outcome in PCNSL Patients Treated with High-Dose Methotrexate and Deferred Radiation
Neurol 70:401-402, Gerstner,E.R.,et al, 2008
Reduction of Disease Activity and Disability With High-Dose Cyclophosphamide in Patients With Aggressive Multiple Sclerosis
Arch Neurol 65:1044-1051, Krishnan,C.,et al., 2008
Immunosuppressant Drugs for Myasthenia Gravis
JNNP 80:5-6, Hart,I.K.,et al, 2008
How Effective Are Disease-Modifying Drugs in Delaying Progression in Relapsing-Onset MS?
Neurol 69:1498-1507, Brown,M.G.,et al, 2007
Efficacy and Safety of Sodium Oxybate in Isolated Focal Laryngeal Dystonia:A Phase IIb Double-Blind Placebo-Controlled Cross-Over Randomized Clinical Trial
Ann Neurol 97:329-343, Simonyan,K.,et al, 2025
FUTURE-AI: International Consensus Guideline for Trustworthy and Deployable Artificial Intelligence in Healthcare
BMJ 388:e081554, Lekadir,K.,et al, 2025
Commonly Used Interventional Procedures for Non-Cancer Chronic Spine Pain: A Clinical Practice Guideline
BMJ 388:e079970, Busse,J.W.,et al, 2025
Embolization of the Middle Meningeal Artery for Chronic Subdural Hematoma
NEJM 392:855-864, 918, Fiorella,D.,et al, 2025
Calcitonin Gene-Related Peptide-Targeted Therapy in Migraine: Current Role and Future Perspectives
Lancet 405:1014-1026, Versijpt,J.,et al, 2025
Submaxiomal Angioplasty for Severe Intracranial Atherosclerotic Stenosis":Benefit of Revascularization at Last
Stroke 56:e114-e118, Pensatok,U.,et al, 2025
Alteplase for Posterior Circulation Ischemic Stropke at 4.5 to 24 Hours
NEJM 392:1288-1296, Yan,S.,et al, 2025
Left Atrial Appendage Closure After Ablation for Atrial Fibrillation
NEJM 392:1277-1287, Wazni,O.M.,et al, 2025
Long-Term Effects of Antidarsagene Autotemcel for Metachromatic Leukodystrophy
NEJM 392:1609-1620, Fumagalli,F.,et al, 2025
Validation of an Artificial Intelligence-Powered Virtual Assistant for Emergency Triage in Neurology
Neurologist 30:155-163, Alessandro,L.,et al, 2025
Upadacitinib - An Up-and-Comer for Treatment of Giant-Cell Arteritis
NEJM 392:2062-2064, Koster,M.J. & Warrington,K.J., 2025
Patent Foramen Ovale Management for Secondary Stroke Prevention:State-of-the-Art Appraisal of Current Evidence
Stroke 55:236-247, Sposato,L.A.,et al, 2024
Inhibition of CD40L with Frexalimab in Multiple Sclerosis
NEJM 390:589-600, 662, Vermersch,P.,et al, 2024
Tenecteplase for Stroke - Opening the Window?
NEJM 390:760-761, Leifer,D.,, 2024
Transcarotid Arter Revascularization Expanding Our Arsenal for the Management of Symptomatic Carotid Artery Stenosis
Stroke 55:931-933, Palaiodimou,L, 2024
IV Thrombolysis in Basilar Artery Occlusion, Outcomes and Comparison with Endovascular Thrombectomy
Neurol 102:e209249, Raty,S.,et al, 2024
Treatment Modalities and Outcomes in Brainstem Cavernous Malformations: A Large Multicenter Observational Cohort Study
Stroke 55:1151-1160, Lu,J.,et al, 2024
Mechanical Thrombectomy in Anticoagulated Patients with Acute Ischemic Stroke, A Meta-Analysis
Neurologist 29:194-203, Zhang,H.L.,et al, 2024
Early Access to First-Seizure Clinics, Subsequent Outcomes, and Factors Associated with Attendance
JAMA Neurol 81:732-740, Li,Y., et al, 2024
Pomalidomide for Epistaxis in Hereditary Hemorrhagic Telangiectasia
NEJM 391:1015-1027, Al-Samkari,H.,et al, 2024
Intravenous Thrombolysis in Patients with Cervical Artery Dissection
Neurol 103:e209843, Shu,L.,et al, 2024